06463922 phase 2 trial has started

A phase 2 trial for 06463922 –¬†lorlatinib by Pfizer has started. To find out more details go to clinicaltrials.gov.

This entry was posted in 3922 - lorlatinib by Pfizer, Lung cancer, Potential Treatments. Bookmark the permalink.

Leave a Reply